| 研究業績：論文 |
・Muso E, Ito-Ihara T, Ono T, Imai E, Yamagata K, Akamatsu A, Suzuki K.：Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis. 57(5):17-8（2004）
・Tanaka M, Yamada S, Iwasaki Y, Sugishita T, Yonemoto S, Tsukamoto T, Fukui S, Takasu K, Muso E.：Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract. 112(2):71-8 (2009)
・Muso E, Okuzaki D, Kobayashi S, Iwasaki Y, Sakurai MA, Ito A, Nojima H.：Ficolin-1 is up-regulated in leukocytes and glomeruli from microscopic polyangiitis patients.Autoimmunity. Dec;46(8):513-24 (2013)
・武曾惠理：～男女共同参画委員会より～ 学会での男女共同参画活動の展望 －日本腎臓学会からの提言－ 肝臓 vol.55 no.7 一般社団法人日本肝臓学会 pp.413-417 ( 2014.)
・Tobino K, Muso E, Iwasaki Y, Yonemoto S, Kasuno K, Tsukamoto T, Nakamura H, Tomino Y.：Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy. Nephrology (Carlton). May;20(5):368-74.(2015)
・Muso E, Mune M, Hirano T, et al : A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. Nephron Extra.29;5(2):ｐｐ58-66 ,(2015 )
・武曾惠理：特集/腎臓病療養指導とチーム医療：「腎臓病療養指導とチーム医療」特集に寄せて：日本腎臓学会誌 57(5),p804-805,（2015,）
・武曾惠理、垣田浩子：総説 多彩な原因疾患による難治性ネフローゼ症候群に対するアフェレシス療法の効果－現況と今後の展望－：日本アフェレシス学会誌 37巻1号 pp24-34(2018)
・Handa T, Kakita H, Tateishi Y, Endo T, Suzuki H, Katayama T, Tsukamoto T, Muso E：The features in IgA-dominant infection-related glomerulonephritis distinct from IgA nephropathy:a single-center study：Clinical and Experimental Nephrology Published online:21 March (2018)
・武曾惠理：特集「IgA腎症―診断・治療の最新動向―」IgA腎症の治療学 7.抗血小板・抗凝固治療：日本臨牀 第77巻・第4号 pp696‐702（2019.）
・Saito T , Muso ,E et al Apolipoprotein E-related glomerular disorders :Kidney Int. Feb;97(2):279-288 2020
・Uno K., Muso E. et al. Impaired HVJ-stimulated Interferon producing capacity in MPO-ANCA-associated vasculitis with rapidly progressive glomerulonephritis lead to susceptibility to infection」Cytokine. Dec;136:155221. 2020
・Wada T., Hara A, Muso E, et al .: Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clin.Exp.Nephrol. 25.1-8, 2021 |
